Here are the 10-K annual reports from Sagimet Biosciences Inc. (SGMT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SGMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMT filings page.
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on fatty acid synthase (FASN) inhibitors for liver disease, acne and cancer. Its lead oral FASN inhibitor, denifanstat, achieved statistically significant Phase 2b results in MASH, improving liver fat, inflammation and fibrosis biomarkers and was generally well tolerated.
Denifanstat received FDA Breakthrough Therapy designation in October 2024 for non-cirrhotic MASH with F2–F3 fibrosis, and Sagimet has completed end-of-Phase 2 FDA interactions. A Phase 1 pharmacokinetic trial combining denifanstat with THR-β agonist resmetirom showed no safety signals, supporting a planned Phase 2 proof-of-concept trial in F4 MASH in the second half of 2026, subject to regulatory consultation.
In acne, China partner Ascletis reported that denifanstat met all primary and secondary endpoints in a 480-patient Phase 3 trial in moderate to severe acne and that the China NMPA accepted its NDA in December 2025. An open-label Phase 3 extension showed generally well-tolerated long-term use. Sagimet is also developing oral FASN inhibitor TVB-3567, now in a first-in-human Phase 1 acne study with a Phase 2 start anticipated in 2026, and is exploring oncology applications where tumors depend on FASN-driven lipid metabolism.